Figure 2.

Generation and characterization of induced pluripotent stem cells (iPSCs) derived from bvFTD patients. (A) Expression of undifferentiated pluripotent stem cell markers in the established iPSC lines from control and two bvFTD patients. octamer-binding transcription factor-4 (OCT4, red), NANOG (red), SRY-box transcription factor 2 (SOX2, green), stage-specific embryonic antigen 4 (SSEA4, red) and tumor rejection antigen-1-81 (TRA-1-81, red). (B) Immunofluorescence analysis showing the differentiation potential of iPSC lines into three germ layers, including ectoderm type III β-tubulin (TUJ1, green), mesoderm smooth muscle actin (SMA, green), and endoderm α-fetoprotein (AFP, red). Scale bar: 100 µm. (C) Karyotype analysis of the control and bvFTD-patient-derived iPSC lines. (D) Sendai virus vector clearance was confirmed by reverse transcription polymerase chain reaction (RT-PCR) (E) Mycoplasma contamination was confirmed from genomic DNA using the PCR-based e-Myco^TM VALiD mycoplasma detection kit (iNtRON, Korea).